Sumary of We can expect more COVID drugs next year. But we’ve wasted so much time getting here:
- Several COVID drugs are in the pipeline for 2022, some you can potentially take at home, others for use in hospital.
- However, as we argue in our paper, with more and larger collaborations, and focusing on repurposing the right drugs, we could have developed effective COVID drugs at scale, earlier.
- Here are some more First, some good news One recent study found a commonly prescribed drug for depression, fluvoxamine, given to people diagnosed with COVID-19 reduced their chance of symptoms deteriorating, needing to go to hospital, and dying.
- It was based on: an existing human drug: drugs designed for another purpose can have extra therapeutic benefits.
- However, this example is the exception rather than the rule when it comes to finding COVID drugs.
- This involves treating the body’s overwhelming response to the virus and the cause of most death and disease.
- However, we didn’t see any major strategy to “treat the host” in the early part of the pandemic, except with the decades-old corticosteroid drugs dexamethasone and budesonide.
- Focusing more on “treating the host” would have bought us time to produce vaccines and antiviral drugs, which typically take longer to develop.